Reading VOR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VOR free→Reading VOR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VOR free→QuarterlyIQ Insights · VOR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Regulation FD Disclosure. On March 27, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933…
Entry into a Material Definitive Agreement. On March 26, 2026, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with TCGX (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the “Shares”) of the Company’s common stock, at a price per Share of $14.05, for gross proceeds of approximately $75.0 million (the “Private Pl…
The Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. Each Investor has represented that it is a “qualified institutional buyer,” as defined in Rule 144A under the Securities Act or an institutional “accredited investor” (as defined in Rule 501(a) under the Securities Act), that it is purchasing the Shares solely for such Investor’s own account a…
Results of Operations and Financial Condition. On January 12, 2026, Vor Biopharma Inc. (the “Company”) released the Presentation (as defined below), which includes the following selected preliminary financial information for the fiscal year ended December 31, 2025: As of December 31, 2025, the Company’s cash, cash equivalents and short-term investments were approximately $450 million. The cash, cash equivalents and short-term investments information above and in the Presentation is preliminar…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 31, 2025, Vor Biopharma Inc. (the “Company”) entered into a separation agreement (the “Separation Agreement”) with Dr. Qing Zuraw, the Company’s Chief Development Officer, as a result of Dr. Zuraw’s decision to pursue other opportunities. Pursuant to the Separation Agreement, Dr. Zuraw’s employment with the Company ended on December 31,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (a), (d) On December 17, 2025, Sarah Reed, a member of the Company’s Board of Directors (the “Board”), delivered her notice of resignation to the Board, effective immediately. Ms. Reed’s decision to resign was not as a result of any disagreement with the Company. The Board thanks Ms. Reed for her service to the Company. On December 18, 2025, the Bo…
The Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. Each of the Investors has represented that it is a “qualified institutional buyer,” as defined in Rule 144A under the Securities Act or an institutional “accredited investor” (as defined in Rule 501(a) under the Securities Act), that it is purchasing the Shares solely for the Investor’s own ac…
Regulation FD Disclosure. On December 15, 2025, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1…
Entry into a Material Definitive Agreement. On December 15, 2025, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 13,876,032 shares (the “Shares”) of the Company’s common stock, at a price per Share of $10.81, for gross proceeds of approximately $150.0 million (the “Private Placement…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 5, 2025 (the “ Effective Date ”), the board of directors (the “ Board ”) of Vor Biopharma Inc. (the “ Company ”) approved a stock option repricing whereby the exercise price of certain outstanding options to purchase shares of the Company’s common stock (the “ Common Stock ”) under the Company’s Amended and Restated 2021 Equity Incentiv…
Other Events. On November 10, 2025, Vor Biopharma Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, Citigroup Global Markets Inc. and TD Securities (USA) LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 10,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Equity Offe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 2, 2025 (the “Effective Date”), Vor Biopharma Inc. (the “Company”) and Dr. Qing Zuraw, the Company’s Chief Development Officer, entered into an amendment (the “Employment Agreement Amendment”) to Dr. Zuraw’s employment agreement with the Company dated July 17, 2025 (the “Employment Agreement”). The Employment Agreement Amendment provide…
Material Modification to Rights of Security Holders. On September 17, 2025, Vor Biopharma Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of 1-for-20 (the “ Charter Amendment ”). The Charter Amendment was authorized by the stockholders of the Company at the Company’s Special Meeting of Stockholders held on August 25, 2025. Pursuant to…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers The Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) approved an amendment and restatement of the Vor Biopharma Inc. 2021 Equity Incentive Plan to, among other things, (i) increase the number of shares of Common Stock reserved for issuance thereunder by 25,000,000 shares and (ii) decrease the number of shares that will automati…
Other Events. On August 27, 2025, in connection with the Company’s existing at-the-market sales program, the Company filed a prospectus supplement (“Prospectus Supplement”) to its effective shelf registration statement on Form S-3 (File No. 333-285969) (the “2025 Form S-3”). The 2025 Form S-3 replaced the prior registration statement on Form S-3 (File No. 333-263541) which expired in March 2025. The Company filed the Prospectus Supplement for the purpose of registering the offer and sale of s…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (a) Resignation of Joshua Resnick, M.D. as a Director On August 25, 2025, Joshua Resnick, M.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation to the Board, effective immediately. Dr. Resnick’s decision to resign was not as a result of any disagreement with the Company. Th…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (a) Resignation of Sven (Bill) Ante Lundberg as a Director On July 17, 2025, Sven (Bill) Ante Lundberg, M.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation to the Board, effective immediately. Dr. Lundberg’s decision to resign was not as a result of any disagreement with…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 9, 2025, the board of directors (the “Board”) of Vor Biopharma Inc. (the “Company”) appointed Sandesh Mahatme as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective immediately. There is no arrangement or understanding between Mr. Mahatme and any other person pursuant to which he wa…
Entry into a Material Definitive Agreement. Telitacicept License Agreement On June 25, 2025, Vor Biopharma Inc. (the “ Company ”) and RemeGen Co., Ltd. (“ RemeGen ”) entered into a license agreement (the “ License Agreement ”) granting the Company exclusive rights to develop and commercialize RemeGen’s proprietary fusion protein product, telitacicept, and related products (the “ Licensed Products ”) outside of the People’s Republic of China (“ PRC ”), Hong Kong, Macau and Taiwan (“ Greater Ch…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Dr. Robert Ang as Chief Executive Officer, President, Director, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer; Transition Agreement On June 25, 2025, Robert Ang, M.B.B.S., M.B.A. notified the Company of his resignation from the positions of Chief Executive Officer, President, Director, Prin…
The RemeGen Warrant and the Pre-Funded Warrants have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. The RemeGen Warrantholder has represented that it is an institutional “accredited investor” as defined in Rule 501 under the Securities Act, that it is acquiring the RemeGen Warrant solely for its own account and not for the account of others, and not wit…
Termination of a Material Definitive Agreement. On June 20, 2025, the Company entered into a Termination Agreement (the “ Termination Agreement ”) with PPF Off 100 Cambridge Park Drive, LLC, a Delaware limited liability company (the “ Landlord ”), pursuant to which the Company and the Landlord agreed to terminate that certain lease agreement (as amended, the “ Lease ”) originally dated as of December 17, 2019, as amended by that certain First Amendment to Lease, dated as of June 15, 2021, and…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Principal Financial Officer and Principal Accounting Officer On May 19, 2024, the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s principal financial officer and principal…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As part of the workforce reduction plan described above in Item 2.05, on May 8, 2025, the Company terminated the employment of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD as Chief Scientific Officer and Head of Technical Operations, effective as of May 16, 2025 (the “Separation Date”), without cause. In connection with their dep…
Other Events. On May 8, 2025, the Company issued a press release announcing that it is initiating a process to explore strategic alternatives to maximize shareholder value. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “antici…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.